2019 ASCO Interview with Dr. Nicholas Vogelzang

June 7, 2019 By swarren

Each year, the American Society of Clinical Oncology unites oncologists from all over the country at the organization’s annual meeting. This year, we spoke with leading oncologist Dr. Nicholas Vogelzang and his son, our Lead Counsel Nicholas Vogelzang, about this year’s theme: Caring for every patient; learning from every patient. As a law firm that…

Dr. Nicholas Vogelzang Discusses Developments in Mesothelioma Treatment

June 7, 2018 By swarren

Dr. Nicholas Vogelzang, long respected for his groundbreaking work in mesothelioma treatment, was inducted to the Giants of Cancer Care®  in a special ceremony at Adler Planetarium on May 31. This honor comes as recognition of Dr. Vogelzang’s revolutionary research and success treating genitourinary cancers including bladder and kidney cancer. The award celebrates leaders in…

Asbestos-caused Cancer Blindsides Family

April 3, 2018 By Nikoleta Morales

Christian F. Hagn, Jr. from Chicago wishes he had known more about asbestos before he abruptly lost his 66-year-old father, Christian A. Hagn, Sr. (1938-2004), to mesothelioma.

“My dad got exposed on the job. I hope I wasn’t exposed, too,” said Christian, Jr. “Companies know that asbestos is killing people, but they keep it on the low. My dad had no protection. They told him it was just dust. Just clean your face, wash your clothes in the laundry, and everything will be fine. It was cheaper for them to lie.”

Defendant’s ‘Lack of Personal Jurisdiction’ Defense Denied

March 6, 2018 By swarren

A Cook County Court will see a case against a North Dakota company, thanks to a momentous order by Honorable Judge Clare E. McWilliams granting personal jurisdiction to the Illinois forum. The February 20th order in the John C. Clark v. A.W. Chesterton Company, et al. case sets a new precedent for Illinois residents seeking…

Vogelzang Law News

UNIVERSITY OF CHICAGO MESOTHELIOMA DRUG TRIALS NEW HOPE FOR MESOTHELIOMA PATIENTS

July 29, 2016 By Vogelzang Law Webmaster

A clinical study of malignant pleural mesothelioma patients treated with investigational cancer vaccine CRS-207 at University of Chicago Medical Center, UCSF’s cancer center, the Moffitt Cancer Center in Tampa, the Abramson Cancer Center in Philadelphia and the National Cancer Institutein Bethesda, Maryland has shown promising results in shrinking tumors. CRS-207 caused tumor shrinkage in 85% of…